Literature DB >> 20884719

Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked.

Michelle Ann Elliott1, Animesh Pardanani, Terra L Lasho, Susan M Schwager, Ayalew Tefferi.   

Abstract

In a retrospective analysis of 205 patients (median age 62 years) with primary myelofibrosis and known JAK2V617F mutational status, 13.2% experienced a vaso-occlusive event at or prior to their diagnosis. After a median follow up of 31 months, post-diagnosis thrombosis occurred in 22 patients (10.7%), including 9 (4.4%) and 16 (7.8%) patients with a total of 9 arterial and 24 venous events, respectively. The majority (71%) of the venous events were temporally associated with other exogenous risk factors for thrombosis such as surgery, line placement or hormonal therapy. On multivariable analysis that included age, JAK2V617F mutation status and leukocyte count as covariates, history of thrombosis was the only predictive variable in general (P=0.04) or when arterial (P=0.007) and venous (P=0.02) thromboses were analyzed separately. The current study demonstrates a higher prevalence of venous, as opposed to arterial, events in PMF, post-diagnosis, and clarifies their nature as being mostly provoked.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884719      PMCID: PMC2948107          DOI: 10.3324/haematol.2010.025064

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  22 in total

1.  Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.

Authors:  A Falanga; M Marchetti; V Evangelista; A Vignoli; M Licini; M Balicco; S Manarini; G Finazzi; C Cerletti; T Barbui
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

2.  Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Authors:  Alessandra Carobbio; Guido Finazzi; Vittoria Guerini; Orietta Spinelli; Federica Delaini; Roberto Marchioli; Giovanna Borrelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

3.  The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.

Authors:  Betty Cheung; Deepti Radia; Panagiotis Pantelidis; Ghasem Yadegarfar; Claire Harrison
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

4.  Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.

Authors:  Guido Finazzi; Alessandro Rambaldi; Vittoria Guerini; Alessandra Carobbo; Tiziano Barbui
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

5.  Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.

Authors:  Roberto Marchioli; Guido Finazzi; Raffaele Landolfi; Jack Kutti; Heinz Gisslinger; Carlo Patrono; Raphael Marilus; Ana Villegas; Gianni Tognoni; Tiziano Barbui
Journal:  J Clin Oncol       Date:  2005-02-14       Impact factor: 44.544

6.  Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution.

Authors:  F Cervantes; A Alvarez-Larrán; E Arellano-Rodrigo; M Granell; A Domingo; E Montserrat
Journal:  Leukemia       Date:  2006-01       Impact factor: 11.528

7.  Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.

Authors:  Raffaele Landolfi; Leonardo Di Gennaro; Tiziano Barbui; Valerio De Stefano; Guido Finazzi; Rosamaria Marfisi; Gianni Tognoni; Roberto Marchioli
Journal:  Blood       Date:  2006-11-14       Impact factor: 22.113

8.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

9.  Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors:  Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

10.  Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia.

Authors:  S Cortelazzo; P Viero; G Finazzi; A D'Emilio; F Rodeghiero; T Barbui
Journal:  J Clin Oncol       Date:  1990-03       Impact factor: 44.544

View more
  3 in total

Review 1.  The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.

Authors:  Devendra Kc; Lorenzo Falchi; Srdan Verstovsek
Journal:  Ann Hematol       Date:  2017-08-14       Impact factor: 3.673

2.  Azygos continuation of the caudal vena cava with segmental aneurysm, lung lobe torsion and pulmonary thromboembolism in a dog.

Authors:  Ashley J Lockwood; Virginia B Sinnott-Stutzman; Pamela J Mouser; Steven L Tsai
Journal:  Clin Case Rep       Date:  2018-01-04

3.  Multi-focal Lytic Lesions in a Patient with Myelofibrosis: A Case Report.

Authors:  Robert R Burnham; Bailey Johnson; Laurie M Lomasney; Dariusz Borys; Anna R Cooper
Journal:  Cureus       Date:  2020-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.